GeoVax appoints Dr. Jayne Morgan to Board; adopts 2023 Stock Incentive Plan

GeoVax Labs, Inc.

Appointed Jayne Morgan, M.D. to Board effective Dec 7, 2022; brings expertise in COVID-19 management and health equity.
Morgan will serve on Nominating & Governance Committee and receive pro-rata director compensation.
Board approved 2023 Stock Incentive Plan, subject to shareholder approval, authorizing up to 3M shares of common stock.
2023 Plan replaces 2020 Stock Incentive Plan; no further grants under Prior Plan after effective date.

item 5.02 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Appointed

Jayne Morgan, M.D.

Director

GOVX · GeoVax Labs, Inc.

Effective: 2022-12-07
Filed: December 8, 2022, 6:59 PM ET

On December 7, 2022, our Board of Directors (the “Board”) appointed Jayne Morgan, M.D. to the Board, effective as of December 7, 2022.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 1.0

Jayne Morgan, M.D. was appointed as Director at GeoVax Labs, Inc..

Action: appointed
Role: Director

Exact text from the filing

On December 7, 2022, our Board of Directors (the “Board”) appointed Jayne Morgan, M.D. to the Board, effective as of December 7, 2022.

View on SEC.gov

GeoVax Labs, Inc. filing history →

Source: SEC EDGAR

accession 0001437749-22-028740

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.